文献速递肾癌与肾肿瘤

肾肿块患者全活检策略:模拟随机对照试验

Biopsy-all strategy in patients with a renal mass: simulation of a randomised controlled trial.
PubMed 文献 · BJU Int · 2025-08-27

结果显示全活检策略可避免6.7%的手术,减少总体并发症3.0%、Clavien-Dindo>II级2.5%、>III级0.5%,人均费用净差为-840美元。

要点

  • 全活检策略可避免6.7%的手术,减少不必要手术。
  • 并发症避免率:总体3.0%,Clavien-Dindo>II级2.5%,>III级0.5%。
  • 人均费用净差为-840美元,提示节省医疗支出。

核心结论

  • 对肾肿块患者非选择性使用肾活检可避免相当数量的手术、少量但存在的并发症,并降低医疗支出。

主要发现

  • 全活检策略预期避免手术率为6.7%。
  • 避免总体并发症率为3.0%,Clavien-Dindo>II级为2.5%,>III级为0.5%。
  • 人均费用净差为-840美元(相对直接手术组)。

关键数值与推荐

  • 模拟假设肾活检组织学不确定率为8-20%,活检相关并发症率为0.07%。
  • 活检组中恶性或不确定组织学患者接受手术,良性组织学患者并发症率为0%。

临床怎么用

  • 对cT1-2 cM0肾肿块患者可考虑全活检策略以减少不必要手术和并发症,并节省费用。

局限性

  • 研究为模拟模型,非真实随机对照试验,结果受假设参数影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To investigate the clinical benefit and cost-effectiveness of a renal biopsy (RB)-all strategy for patients with a renal mass, as in renal cancer the indication for upfront surgery (SUR) without previous RB invariably results in the overtreatment of patients with benign histology. PATIENTS AND METHODS: A total of 1729 patients with clinical (c)T1-2 cM0 renal mass treated with SUR were included. To simulate a randomised clinical trial comparing patients who underwent SUR vs RB and subsequent treatment, a random binary variable assigned patients to Arm a-SUR and Arm b-RB. In Arm a-SUR, patients are all treated with SUR; postoperative complications and costs are those recorded after surgery. In Arm b-RB, we have assumed an 8-20% uncertain RB histology rate and a 0.07% RB-related complication rate to build our simulation model. Patients are selected for RB and subsequently for surgery in case of malignant or uncertain RB histology; complications are those recorded after surgery in case of malignant or uncertain RB histology, but 0% in case of benign histology. The outcomes of the study were the rate of SUR avoided, the rate of Clavien-Dindo Grade specific complications avoided, and the net difference in per-patient cost in Arm b-RB relative to Arm a-SUR. In all, 10 000 individual iterations of the simulation model were performed and among all iterations, the median and 95% confidence intervals were computed. RESULTS: If a RB-all strategy is implemented, the expected rate of SUR avoided is 6.7%. The rate of overall, Clavien-Dindo Grade >II, and Clavien-Dindo Grade >III complications avoided is 3.0%, 2.5%, and 0.5%, respectively, and the average net difference in per-patient cost was -$840 (US dollars). CONCLUSIONS: The non-selective use of RB in patients with a renal mass avoids a significant number of SUR, a marginal but existing number of complications, and is associated with decreased healthcare expenditures.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Belladelli F, Rosiello G, Salerno L, et al. Biopsy-all strategy in patients with a renal mass: simulation of a randomised controlled trial. BJU Int. 2025. PMID: 40859780. doi:10.1111/bju.16885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。